Vaccine against brucellosis in humans - contg. phenol insoluble fraction of defatted Brucella abortus cells

Vaccine against brucellosis comprises, in a suitable vehicle, the phenol-insoluble fraction (A) of Brucella abortus, esp. the strain B19. Pref. (A) is 1.7-2.3, esp. 2, mg (dry basis) per ml solvent and the vaccine is esp. formulated in unit doses of 0.5 ml. The pref. vehicle is a phenol-contg. physiological solvent. The vaccine is made from intact B.abortus cells by (1) removal of lipids; (2) drying; (3) extracting with phenol (esp. phenol satd. with water), at about 60 deg.C; (4) washing the filtered and purified prod. and (5) forming into a homogeneous, sterile suspension. The vaccine is suitable for admin. to humans, e.g. farm workers or veterinary surgeons, and is effective against B. melitensis and B. suis as well as B. abortus. It is nontoxic and induces only very mild hypersensitivity reactions. LE VACCIN EST CARACTERISE EN CE QU'IL COMPORTE, DANS UN VEHICULE CONVENABLE, LA FRACTION PHENOL-INSOLUBLE DE BRUCELLA ABORTUS, NOTAMMENT BRUCELLA ABORTUSB19. LE VACCIN EST UTILISABLE CHEZ L'HOMME ET PRESENTE UNE PROTECTION HOMOLOGUE ET HETEROLOGUE POUR BRUCELLA MELITENSIS ET BRUCELLA SUIS.